Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02850640
Other study ID # 2015/2781
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date December 2015
Est. completion date July 1, 2024

Study information

Verified date October 2023
Source Duke-NUS Graduate Medical School
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cost and Medical Care of Patients with Advanced Serious Illness in Singapore (COMPASS),is a cohort study which aims to capture health care utilization, cost, and quality of life indicators of patients with advanced cancer and their primary caregivers.


Description:

The study will recruit 600 patients with advanced cancer, their primary informal caregivers and their treating physicians. Eligible patients will be recruited from study-sites in Singapore and will be followed until death. Patients and their consenting primary informal caregivers will be interviewed first at baseline and then every 3 months thereafter until the patient's death. A post-death interview with primary informal caregiver will be conducted at 8th week and 6 months after the patient's death. As the majority of the care during last year of life is provided by hospices, the eligible patients will be followed as they receive treatment and care at various hospices. Treating physicians of the patients will be invited to take part in the study. They will be asked to answer a survey conducted only once during the duration of the study. Data on medical expenditures incurred by a patient from diagnosis of advanced cancer until death will be collected. With patient consent, these data will be extracted every 6 months from the time of patient enrolment from relevant databases, including hospitals and hospices.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 600
Est. completion date July 1, 2024
Est. primary completion date July 1, 2024
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria for patients are: 1. Age = 21 years old 2. Singaporean or Singapore Permanent Resident 3. Diagnosis of advanced/ stage IV solid cancer (for non-breast and non-prostate cancer patients). If it is breast or prostate cancer it should be stage IV with metastases to an organ site. 4. Graded 0-2 on the Eastern Cooperative Oncology Group Performance Status 5. Intact cognition (of patients =60 years of age) as determined by the Abbreviated Mental Test. If patient fails the cognitive test, he/she continues to be eligible for the study although self-reported data will no longer be collected. The Legal Representative of the patient will be approached for providing consent on behalf of the patient, to allow access to review of patient's medical and billing records The exclusion criteria for patients are 1. Patients who are not Singaporeans or Singapore Permanent Residents 2. Patients who are graded 3 (confined to bed more than 50% of waking hours) and 4 (completely disabled) on the Eastern Cooperative Oncology Group Performance Status. 3. Patients who are =21 years of age The inclusion criteria for primary informal caregivers are: 1. Age = 21 years old 2. Main person or one of the main providing care to the patient (e.g. accompanying patient for doctor's visits, helping the patient with day to day activities) 3. Main person or one of the main ensuring provision of care (e.g. supervision of foreign domestic worker so that the patient is looked after) 4. Main person or one of the main involved in making decisions regarding treatment the patient receives 5. Patient they are caring for is enrolled in the study The exclusion criteria for primary informal caregivers are: a) Foreign domestic workers/ maids will be excluded from this study The inclusion criteria for physicians are: 1. Age = 21 years old 2. Patients they are treating are enrolled in the study

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Singapore National Cancer Centre Singapore Singapore
Singapore National University Hospital Singapore

Sponsors (3)

Lead Sponsor Collaborator
Duke-NUS Graduate Medical School National Cancer Centre, Singapore, National University Hospital, Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in overall quality of life among patients through the last year of life. We will assess patient's quality of life through FACT-G From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Primary Change in anxiety and depression among patients through the last year of life We will assess patients' anxiety and depression through the Hospital Anxiety and Depression Scale (HADS). From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Primary Change in pain severity among patients through the last year of life We will assess pain reported by patients through visual analog pain scores From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Primary Change in activities of daily living among patients through the last year of life We will assess limitations in activities of daily living of patients through OARS Multidimensional Functional Assessment Questionnaire From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Primary Change in patient's perceived quality of care during the last year of life We will describe patients' assessment of their own care using a scale used by Ayanian et al (JCO, 2010) that consists of 13 questions. From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Primary Total health care expenditure during the last year of life through analysis of medical bills We will calculate total health care expenditure during the last year of patient's life as the sum total of expenditures incurred at clinics etc. From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Secondary Change in patient's awareness of prognosis by asking if the patients believe that their current treatment regimen is likely to cure them of cancer We will assess knowledge of disease by asking the extent to which advanced cancer patients understand the severity of their condition and if the patients believe that a treatment regimen is available that could cure them From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Secondary Change in caregiver burden through the last year of life We will assess caregiver burden through modified Caregiver Reaction Assessment Scale Instrument From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Secondary Change in caregiver's levels of emotional distress through the last year of life We will assess caregiver's anxiety and depression through the Hospital Anxiety and Depression Scale (HADS). From recruitment to death of patient (baseline, 3 month, 6 months, 9 months, 12 months)
Secondary Caregiver's perception of patient's end-of-life care assessed after patient's death We will assess caregiver perceived quality of end-of-life care through Caregiver Evaluation of the Quality of End-Of- Life Care( CEQUEL) 8 weeks bereavement
Secondary Caregivers bereavement adjustment assessed after patient's death Post-patient death bereavement adjustment will be assessed through Brief Grief Questionnaire 6 months bereavement
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients